Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael J. Morin is active.

Publication


Featured researches published by Michael J. Morin.


Cancer Research | 1997

Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase

James D. Moyer; Elsa G. Barbacci; Kenneth K. Iwata; Lee Daniel Arnold; Bruce M. Boman; Ann Cunningham; Catherine DiOrio; Jonathan Doty; Michael J. Morin; Mikel P. Moyer; Mark J. Neveu; Vincent A. Pollack; Leslie R. Pustilnik; Margaret M. Reynolds; Don Sloan; April Theleman; Penny Miller


Journal of Pharmacology and Experimental Therapeutics | 1999

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Vincent A. Pollack; Douglas Savage; Deborah A. Baker; Konstantinos E. Tsaparikos; Donald E. Sloan; James D. Moyer; Elsa G. Barbacci; Leslie R. Pustilnik; Teresa A. Smolarek; John M. Davis; Madhur P. Vaidya; Lee Daniel Arnold; John L. Doty; Kenneth K. Iwata; Michael J. Morin


Cancer Research | 1984

Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin.

Michael J. Morin; Alan C. Sartorelli


Journal of Cellular Physiology | 1983

The biochemical and ultrastructural effects of tunicamycin and D‐glucosamine in L1210 leukemic cells

Michael J. Morin; Carl W. Porter; Patricia McKernan; Ralph J. Bernacki


Journal of Medicinal Chemistry | 1980

Halogenated L-fucose and D-galactose analogues: synthesis and metabolic effects.

Janice R. Sufrin; Ralph J. Bernacki; Michael J. Morin; Walter Korytnyk


Cancer Research | 1983

Biochemical Effects and Therapeutic Potential of Tunicamycin in Murine L1210 Leukemia

Michael J. Morin; Ralph J. Bernacki


Biochemical Pharmacology | 1983

Effects of a membrane sugar analogue, 6-deoxy-6-fluoro-d-galactose, on the L1210 leukemic cell ectosialyltransferase system

Michael J. Morin; Carl W. Porter; Charles R. Petrie; Walter Korytnyk; Ralph J. Bernacki


Archive | 2000

Polymorphe stable de chlorhydrate de n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, et methodes de production et utilisations pharmaceutiques dudit polymorphe

Richard D. Connell; James D. Moyer; Michael J. Morin; Shama Kajiji; Barbara A. Foster; Karen J. Ferrante; Timothy Norris; Jeffrey W. Raggon; Sandra L Silberman


Archive | 2000

POLIMORFO ESTABLE DE CLORHIDRATO DE N-(3-ETINILFENILAMINO)-6,7-BIS(2-METOXIETOXI)-4-QUINAZOLINAMINA,PROCEDIMIENTOS DE PRODUCCION Y USOS FARMACEUTICOS DEL MISMO.

Richard D. Connell; Karen J. Ferrante; Barbara A. Foster; Shama Kajiji; Michael J. Morin; James D. Moyer; Timothy Norris; Jeffrey W. Raggon; Sandra L Silberman


Archive | 2000

N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin zur behandlung von nsclc

Richard D. Connell; James D. Moyer; Michael J. Morin; Shama Kajiji; Barbara A. Foster; Karen J. Ferrante; Timothy Norris; Jeffrey W. Raggon; Sandra L Silberman

Collaboration


Dive into the Michael J. Morin's collaboration.

Top Co-Authors

Avatar

Barbara A. Foster

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ralph J. Bernacki

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Carl W. Porter

Roswell Park Cancer Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge